[News] Dasatinib in paediatric chronic myeloid leukaemias

Treatment with the tyrosine kinase inhibitor (TKI) dasatinib achieved clinically important responses in paediatric patients with chronic myeloid leukaemia (CML) in a phase 2, non-randomised trial.

Source: The Lancet Oncology - March 8, 2018 Category: Cancer & Oncology Authors: Priya Venkatesan Tags: News Source Type: research